Key result
SSRIs interact with methadone to potentiate QT prolongation and cardiotoxicity.
Why the study?
Methadone maintenance therapy is associated with QT interval prolongation and frequent concurrent SSRI use, raising concerns about drug interactions and cardiotoxicity.
Does concurrent SSRI use potentiate methadone cardiotoxicity (QT prolongation) in patients on methadone maintenance therapy?
Does concurrent SSRI use potentiate methadone cardiotoxicity (QT prolongation) in patients on methadone maintenance therapy?
Concurrent use of SSRIs in patients on methadone maintenance therapy carries a high potential for drug interactions leading to QT prolongation and cardiotoxicity.
May warrant ECG monitoring with concurrent methadone-SSRI use; leaves open need for prospective confirmation of interaction risk.
Methadone maintenance therapy, commonly used in the treatment of opioid use disorder, has been associated with electrocardiographic QT interval prolongation.1 With comorbid mental illness often seen in methadone‐treated patients,2 concurrent antidepressant use is likely. This results in a high potential for drug interaction, especially with selective serotonin reuptake inhibitors (SSRIs).
No takes yet. Share an insight, caveat, or question.
Y. W. Francis Lam (2022) studied this question. Selective serotonin reuptake inhibitors (SSRIs) have a high potential to interact with methadone and potentiate methadone-induced QT interval prolongation and cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: